-
Key Brands
-
Revenue
-
Performance
| Eltroxin | Imuran | Lipitor | Lyrica | Meticorten | Zyloric |
|---|---|---|---|---|---|
| Thyroid hormone | Immuno- suppressant |
Cardiovascular | Anticonvulsant and neuropathy |
Corticosteroid | Anti-gout preparation |
2025
29%
of Group revenue
40%
of Group gross profit
Africa Middle East
36
Americas
27
Australasia
19
Asia
10
Europe CIS
8
| Revenue | 2025 R'million |
2024 R'million |
% Change Reported |
CER |
|---|---|---|---|---|
| Africa Middle East | 4 569 | 4 242 | 8 | 9 |
| Americas | 3 320 | 2 832 | 17 | 34 |
| Australasia | 2 377 | 2 618 | (9) | (5) |
| Asia | 1 210 | 697 | 74 | 78 |
| Europe CIS | 1 043 | 991 | 5 | 7 |
| Total | 12 519 | 11 380 | 10 | 16 |
| Gross profit (%) | 61.8 | 60.9 |
Prescription brands achieved robust growth of 10% (16% CER), with revenue reaching R12 519 million. This growth was primarily driven by the Americas, which saw a 17% increase (34% CER) benefitting from the full year addition of the portfolio acquired in Latin America, which enjoyed double-digit growth on a comparable basis in H2 2025. Africa Middle East, the largest region within this segment, grew 8% with solid organic growth of 6% augmented by the Lilly franchise. Asia grew by 74% (78% CER), benefitting from the product swop with Sandoz. Solid Europe CIS growth of 5% (7% CER) was supported by core products, while Australasia experienced a 9% decline (-5% CER) due to further regulated price reductions in Australia.The gross profit margin rose to 61,8% (up from 60,9% in FY2024), with the positive impact of the favourable sales mix from Americas
